NeonMind Biosciences Inc. (NMDBF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
NeonMind Biosciences Inc. (NMDBF) trades at $0.0076 with AI Score 44/100 (Grade C). NeonMind Biosciences Inc. focuses on discovering, developing, and commercializing medicinal and psychedelic mushrooms for mental illnesses. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for NMDBF: NMDBF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NMDBF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
NMDBF: the 3 scored disciplines are evenly split. Dominant signal: Seth Klarman bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
NeonMind Biosciences Inc. (NMDBF) Healthcare & Pipeline Overview
NeonMind Biosciences Inc. is a biotechnology company focused on developing medicinal and psychedelic mushroom-based products for mental health and weight management, positioning itself in the emerging market for alternative therapies within the healthcare sector, though it faces regulatory and financial challenges.
What Is the Investment Thesis for NMDBF?
NeonMind Biosciences Inc. presents a speculative investment opportunity within the emerging psychedelic medicine market. The company's focus on developing psilocybin-based products for mental health and weight management aligns with growing interest in alternative therapies. However, the company's OTC listing and limited financial information necessitate caution. Key value drivers include successful clinical trials, regulatory approvals, and strategic partnerships. The company's small market capitalization and negative beta of -0.88 indicate high volatility and sensitivity to market conditions. Upcoming catalysts include progress in research and development, potential collaborations, and evolving regulatory landscape. Investors should carefully consider the risks associated with investing in early-stage biotechnology companies, particularly those involved with controlled substances.
Based on FMP financials and quantitative analysis
NMDBF Key Highlights
NeonMind Biosciences Inc. is focused on the discovery, development, and commercialization of medicinal and psychedelic mushrooms.
- The company is developing psilocybin-based products for mental illnesses and weight management.
- NeonMind Biosciences Inc. was formerly known as Flourish Mushroom Labs Inc. and changed its name in April 2020.
- The company is based in Oakville, Canada, and operates as a subsidiary of The Yield Growth Corp.
- NeonMind Biosciences Inc. trades on the OTC market, indicating higher risk and lower liquidity compared to major exchanges.
Who Are NMDBF's Competitors?
NMDBF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NMDBF's Key Strengths?
Focus on emerging psychedelic medicine market.
- Development of psilocybin-based products.
- Experienced management team.
- Strategic partnerships with key players.
What Are NMDBF's Weaknesses?
Limited financial resources.
- Dependence on regulatory approvals.
- Early stage of development.
- High risk associated with psychedelic substances.
What Could Drive NMDBF Stock Higher?
Progress in research and development of psilocybin-based products.
- Potential collaborations with pharmaceutical companies or research institutions.
- Evolving regulatory landscape regarding psychedelic medicine.
- Increasing societal acceptance of psychedelic therapies.
- Expansion into new therapeutic areas and geographic markets.
What Are the Key Risks for NMDBF?
Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Regulatory hurdles and delays in obtaining approvals.
- Competition from established pharmaceutical companies.
- Negative public perception of psychedelic substances.
- Adverse side effects or safety concerns.
- Limited financial resources and dependence on funding.
What Are the Growth Opportunities for NMDBF?
- Expansion into New Therapeutic Areas: NeonMind Biosciences Inc. can expand its product pipeline to target additional mental health conditions beyond depression and anxiety, such as PTSD and addiction. The market for mental health treatments is substantial, with the global mental health market projected to reach $537.98 billion by 2032. This expansion would require further research and development, clinical trials, and regulatory approvals, with a timeline of 3-5 years for new product launches. Success in this area would diversify the company's revenue streams and reduce its reliance on a limited number of products.
- Strategic Partnerships and Collaborations: NeonMind Biosciences Inc. can pursue strategic partnerships with pharmaceutical companies, research institutions, and healthcare providers to accelerate its research and development efforts and expand its market reach. Collaborations can provide access to funding, expertise, and distribution channels. The timeline for establishing partnerships is typically 1-2 years, with ongoing collaboration efforts. Successful partnerships would enhance the company's credibility and facilitate the commercialization of its products.
- Geographic Expansion into New Markets: NeonMind Biosciences Inc. can expand its operations into new geographic markets, particularly in countries with favorable regulations regarding psychedelic medicine. The North American and European markets are particularly attractive, with increasing acceptance of alternative therapies. This expansion would require navigating regulatory requirements, establishing distribution networks, and adapting its products to local market needs. The timeline for geographic expansion is typically 2-3 years per new market. Successful expansion would increase the company's revenue potential and diversify its geographic risk.
- Development of Novel Delivery Systems: NeonMind Biosciences Inc. can invest in the development of novel delivery systems for its psilocybin-based products, such as sublingual tablets or transdermal patches, to improve bioavailability and patient compliance. The market for advanced drug delivery systems is growing rapidly, with a global market size of $248.7 billion in 2023. This development would require significant research and development efforts, with a timeline of 2-4 years for new delivery system launches. Successful development of novel delivery systems would provide a competitive advantage and enhance the efficacy of its products.
- Capitalizing on the Growing Acceptance of Psychedelic Therapies: As societal acceptance of psychedelic therapies grows, NeonMind Biosciences Inc. can capitalize on this trend by increasing its marketing and education efforts to raise awareness of the potential benefits of its products. This includes participating in industry conferences, publishing research findings, and engaging with patient advocacy groups. The timeline for increasing market awareness is ongoing, with continuous efforts to educate the public and healthcare professionals. Successful marketing and education efforts would drive demand for its products and increase its market share.
What Are NMDBF's Competitive Advantages?
- Proprietary formulations of psilocybin-based products.
- Intellectual property protection through patents and trademarks.
- First-mover advantage in the emerging psychedelic medicine market.
- Strategic partnerships with key players in the healthcare industry.
What Does NMDBF Do?
NeonMind Biosciences Inc., formerly known as Flourish Mushroom Labs Inc., was incorporated in 2019 and rebranded in April 2020 to reflect its focus on psychedelic medicine. Based in Oakville, Canada, the company is dedicated to the discovery, development, and commercialization of medicinal and psychedelic mushrooms, particularly psilocybin-based products, to address mental health challenges and weight management. NeonMind's core strategy revolves around creating innovative products infused with medicinal mushrooms, targeting conditions such as depression, anxiety, and obesity. The company operates as a subsidiary of The Yield Growth Corp. NeonMind is actively involved in research and development, seeking to establish clinical evidence for the efficacy and safety of its products. The company aims to capitalize on the growing interest in alternative therapies and the potential of psychedelic compounds to treat various mental health disorders. NeonMind's product development pipeline includes formulations designed for both therapeutic and nutraceutical applications, reflecting a dual approach to market penetration. The company is navigating the complex regulatory landscape surrounding psychedelic substances, working to comply with evolving regulations and secure necessary approvals for its products. NeonMind Biosciences is positioning itself to be a leader in the emerging field of psychedelic medicine, focusing on innovative product development and strategic partnerships.
What Products and Services Does NMDBF Offer?
- Discovers and develops medicinal mushroom-based products.
- Focuses on psychedelic mushrooms for mental illnesses.
- Develops psilocybin-based products.
- Creates mushroom-infused products for weight loss and management.
- Conducts research and development to establish clinical evidence.
- Navigates the regulatory landscape for psychedelic substances.
- Aims to commercialize its products for therapeutic and nutraceutical applications.
How Does NMDBF Make Money?
- Develops and patents proprietary formulations of psilocybin-based products.
- Conducts clinical trials to demonstrate the efficacy and safety of its products.
- Seeks regulatory approvals from health authorities to market its products.
- Commercializes its products through partnerships with pharmaceutical companies and healthcare providers.
What Industry Does NMDBF Operate In?
NeonMind Biosciences Inc. operates within the rapidly evolving biotechnology sector, specifically targeting the emerging market for psychedelic medicine. The industry is characterized by increasing research into the therapeutic potential of psychedelic compounds, such as psilocybin, for treating mental health disorders and other conditions. The competitive landscape includes companies like Cybin Inc. and MindMed, which are also developing psychedelic-based therapies. The market is subject to evolving regulations and public perception, creating both opportunities and challenges for companies in this space. The global market for psychedelic drugs was valued at $4.88 billion in 2023 and is projected to reach $10.75 billion by 2030, growing at a CAGR of 11.9% from 2023 to 2030.
Who Are NMDBF's Key Customers?
- Individuals seeking alternative treatments for mental health disorders.
- Patients looking for weight management solutions.
- Healthcare providers interested in offering innovative therapies.
- Pharmaceutical companies seeking to expand their product portfolios.
- Research institutions conducting studies on psychedelic medicine.
Financial Health
NeonMind Biosciences Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
NMDBF Valuation & Market Position
Relative to its peer group, NMDBF's quantitative score of 44/100 is below the peer average of 76/100.
Key Financial Metrics
Return on equity for NeonMind Biosciences Inc. stands at 366.6%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.19 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
NeonMind Biosciences Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Oakville, CA. The company is led by CEO Penny Olga White BA, LLB. NMDBF has traded publicly since 2021.
NMDBF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Focus on emerging psychedelic medicine market.
- Development of psilocybin-based products.
- Experienced management team.
- Strategic partnerships with key players.
Bear Case
- Limited financial resources.
- Dependence on regulatory approvals.
- Early stage of development.
- High risk associated with psychedelic substances.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
NMDBF Latest News
No recent news available for NMDBF.
NMDBF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NMDBF.
Price Targets
Wall Street price target analysis for NMDBF.
NMDBF MoonshotScore
What does this score mean?
The MoonshotScore rates NMDBF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Penny Olga White BA, LLB
CEO
Penny White brings a legal background to her role as CEO of NeonMind Biosciences Inc. With a BA and LLB, she likely possesses expertise in regulatory compliance, intellectual property, and corporate governance. Her legal training may be particularly valuable in navigating the complex regulatory landscape surrounding psychedelic substances. Prior to NeonMind, details of her career history are not available, but her legal background suggests experience in corporate law or related fields.
Track Record: As CEO of NeonMind Biosciences Inc., Penny White has overseen the company's efforts to develop and commercialize medicinal and psychedelic mushroom-based products. Specific achievements and milestones under her leadership are not detailed in the provided information, but her role involves guiding the company's strategic direction, securing funding, and navigating the regulatory environment.
NMDBF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that NeonMind Biosciences Inc. may not meet the minimum financial or disclosure requirements of the higher tiers, such as OTCQX or OTCQB. Companies in this tier may have limited financial reporting, making it more difficult for investors to assess their financial health and performance. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face less stringent regulatory oversight and reporting requirements, which can increase investment risk. This tier is often associated with speculative or high-risk investments.
- OTC Tier: OTC Other
- Limited financial disclosure.
- Low trading volume and liquidity.
- Higher price volatility.
- Potential for fraud or manipulation.
- Less regulatory oversight compared to major exchanges.
- Verify the company's registration and legal status.
- Review available financial statements and disclosures.
- Assess the company's management team and their experience.
- Research the company's products and market position.
- Understand the regulatory environment and potential risks.
- Monitor trading volume and price activity.
- Consult with a financial advisor before investing.
- Company is incorporated and has a physical address.
- Company has a website and publishes press releases.
- Company has a management team and board of directors.
- Company is developing products and conducting research.
- Company is seeking regulatory approvals for its products.
What Investors Ask About NeonMind Biosciences Inc. (NMDBF) — Healthcare
What does the AI Score mean for NMDBF?
NMDBF holds an AI Score of 44/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. NeonMind Biosciences Inc. focuses on discovering, developing, and commercializing medicinal and psychedelic mushrooms for mental illnesses. The company is developing psilocybin-based products …
What does NeonMind Biosciences Inc. do?
NeonMind Biosciences Inc. is a biotechnology company focused on the discovery, development, and commercialization of medicinal and psychedelic mushrooms for mental illnesses and weight management. The company is developing psilocybin-based products, including mushroom-infused products, targeting conditions such as depression, anxiety, and obesity.
What do analysts say about NMDBF stock?
There is currently no available analyst coverage or consensus on NMDBF stock. As an OTC-listed company with a small market capitalization, NeonMind Biosciences Inc. may not attract significant analyst attention. Investors should conduct their own due diligence and consider the risks associated with investing in early-stage biotechnology companies, particularly those involved with controlled substances.
What are the main risks for NMDBF?
The main risks for NeonMind Biosciences Inc. include regulatory hurdles and delays in obtaining approvals for its psilocybin-based products, competition from established pharmaceutical companies, negative public perception of psychedelic substances, and potential adverse side effects or safety concerns.
What are the key factors to evaluate for NMDBF?
NeonMind Biosciences Inc. (NMDBF) holds an AI score of 44/100 (low). presents a speculative investment opportunity within the emerging psychedelic medicine market. Not financial advice.
How frequently does NMDBF data refresh on this page?
NMDBF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven NMDBF's recent stock price performance?
NeonMind Biosciences Inc. (NMDBF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on emerging psychedelic medicine market. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NMDBF overvalued or undervalued right now?
NeonMind Biosciences Inc. (NMDBF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research NMDBF before investing?
Before investing in NeonMind Biosciences Inc. (NMDBF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial information available for NeonMind Biosciences Inc.
- OTC listing indicates higher risk and lower liquidity.
- Information based on available sources and may not be comprehensive.